The 2008 WHO classification scheme of hematolymphoid neoplasms recognizes a category of myeloid and lymphoid neoplasms (MLNs) with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. 1 The postulated cell of origin for PDGFRA-or FGFR1-rearranged diseases is a pluripotent progenitor giving rise to either MLNs, or both, including myeloproliferative neoplasms and acute leukemias of myeloid, T-and B-lymphoid lineages.
Historically, PDGFRB translocations have not been associated with malignancies of the lymphoid lineage. Myeloid neoplasms with abnormalities of PDGFRB have been described to have haematological features of chronic myelomonocytic leukemia (CMML), sometimes with eosinophilia, or as various other myeloproliferative and/or myelodysplastic neoplasms. 2 In recognition of this distinction, the classification scheme designates specific categories of "MLNs"
with PDGFRA and FGFR1 rearrangement, but omits the word "lymphoid" from the PDGFRBassociated entity. 1 To call attention to the rare occurrence of lymphoid and mixed MLNs with abnormalities of PDGFRB, we present the clinicopathologic details of two cases.
Case 1: MLN, eosinophilia, and RABEP1-PDGFRB fusion A 64 year-old man with splenomegaly and diffuse lymphadenopathy (supraclavicular, axillary, mediastinal, para-aortic, retroperitoneal, pelvic) was diagnosed with T-lymphoblastic lymphoma (T-LBL) on left cervical lymph node (LN) biopsy. A complete blood count (CBC) showed anemia, thrombocytopenia and mild eosinophilia, but no blasts. (Table 1) . A staging bone marrow (BM) biopsy was abnormal, demonstrating features of a myeloid neoplasm with mixed myeloproliferative/myelodysplastic features but was not involved by T-LBL ( Figure 1 ). He was treated with a vincristine/prednisone-based induction protocol for T-LBL. Following identification of a t(5;17)(q33;p13) in BM and confirmation of PDGFRB rearrangement in the LN and BM samples, imatinib 400mg/day was added, but stopped after 18 days due to drug intolerance. Based on prior literature, FISH studies were subsequently performed that confirmed RABEP1 as the partner gene ( Figure 1 ). 3, 4 Within 3 weeks after discontinuing imatinib, the patient developed increases in the WBC count (18.9 x 10 9 /L) and eosinophil count (8.69 x 10 9 /L) that could not be attributed to an infection or medication, suggesting progression. He ultimately chose hospice care.
Case 2: MLN, eosinophilia and novel C6orf204-PDGFRB fusion A 38 year-old man with diffuse lymphadenopathy and mild splenomegaly was diagnosed with T-LBL on LN biopsy. A CBC was significant for eosinophilia without leukocytosis (Table 1) . Despite chemotherapy (methotrexate, cytarabine, cyclophosphamide, vincristine, doxorubicin, dexamethasone), over the next year, the patient suffered 2 additional relapses of T-LBL with intervening re-induction chemotherapy followed by additional treatment for residual lymphadenopathy (etoposide, cyclophosphamide, methotrexate, and high dose cytarabine). At the time of his second T-LBL relapse, a CBC demonstrated a leukocytosis (WBC: 14.8 x 10 9 /L) with eosinophilia (4.53 x 10 9 /L) and a concurrent BM biopsy was done that showed a myeloid neoplasm with myeloproliferative features (Figure 2 ) without involvement by T-LBL. Karyotyping showed a t(5;6)(q33-34;q23) and subsequent kinase-targeted next generation sequencing demonstrated a novel C6orf204-PDGFRB fusion. 5 The identical translocation was also found in the initial T-LBL. The patient responded well to imatinib 400mg/day for 7 days plus 2 cycles of nelarabine prior to allogeneic peripheral blood stem cell transplant. At the time of transplantation, the patient was not in complete molecular remission, with cytogenetic and FISH evidence of residual PDGFRB translocation (t(5;6) in 11/20 metaphases and FISH positive for PDGFRB in 32.5% of nuclei). Subsequent to transplantation, the patient has remained in clinical complete remission after transplantation for more than three years with no molecular cytogenetic evidence of T-LBL or PDGFRB translocation on numerous biopsies.
Discussion
Myeloid neoplasms with PDGFRB rearrangement are considered a specific entity in the WHO classification and are included in a single category alongside myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA and FGFR1. PDGFRA and FGFR1-related disorders appear to arise from a common pluripotent (myeloid/lymphoid) stem cell since the genetic abnormalities are present in both the myeloid and lymphoid components. However, the PDGFRB category is thought to arise from a myeloid stem cell.
PDGFRB-rearrangements have previously been associated with a diverse group of myeloid neoplasms with eosinophilia. 1 Overall, PDGFRB-related diseases are rare. A study of 556 patients with myeloproliferative neoplasms detected PDGFRB rearrangements in 10 patients (1.8%), all with eosinophilia and generally showing complete response to imatinib therapy. 6 After the identification of ETV6(TEL)-PDGFRB in cases of CMML with t(5;12)(q33;p12) in 1994, 7 over 20 PDGFRB fusion partners have emerged.
PDGFRB encodes the beta chain of the cell surface receptor for platelet derived growth factor (PDGF), a tyrosine kinase (TK) which activates signaling pathways important to cell growth and differentiation. 8, 9 Mutated PDGF signaling components have been identified in a number of neoplasms. Notably, a transgenic mouse model directing the ETV6-PDGFRB fusion protein to lymphoid cells demonstrated the development of B and T-LBLs. 10 This demonstrates that PDGFRB rearrangements have the ability to contribute to the genesis of lymphoid neoplasms in mice, despite the rarity of such an observation in humans. Indeed, the recurring kinase-activating EBF1-PDGFRB fusion was identified in up to 8% of patients with BCR-ABL1-like B-lymphoblastic leukemia (as defined by gene expression profiling) 11 and remission with TK inhibitor therapy was documented.
12
Although T-LBL in conjunction with a myeloproliferative process is not unusual in cases with abnormalities of FGFR1 and/or PDGFRA, it had not been well documented with PDGFRB translocations. A single report of acute myeloid leukemia with t(5;12)(q33;p12) in BM with concurrent T-LBL in a LN biopsy suggested that MLNs with PDGFRB fusion existed, but cytogenetic studies were not performed on LN to confirm this. 13 To our knowledge, the first reported MLN with documented PDGFRB in both processes revealed a novel C6orf204-PDGFRB fusion in a patient using a systematic kinase fusion screen that involved capture of the tyrosine kinase regions, followed by next generation sequencing of the capture products. While the technical aspects related to the fusion detection were published, the clinicopathologic details of that case are described in detail for the first time in the current series (case 2). 
